The study aims to examine the efficacy of a telehealth-delivered cognitive behavioral therapy (CBT) + benzodiazepine taper (BZ-TP) program in facilitating reductions in benzodiazepine use among patients who are prescribed opioids for pain.
Augmenting the Efficacy of Benzodiazepine Taper With Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids
This study will examine the efficacy of adding a cognitive behavioral therapy (CBT) program developed and evaluated for patients with anxiety disorders to a benzodiazepine (BZ) taper as an augmentation strategy to improve the success of benzodiazepine reduction among patients taking concurrent opioid prescriptions for pain. There is a high risk of mortality including fatal overdose among patients taking opioids and BZs, yet it remains a prevalent problem. Treating underlying anxiety contributing to BZ use and potentially implicated in pain has the potential to decrease BZ use and possibly reduce opioid use. Thus, the current study moves the field forward in testing the efficacy of a combined CBT + BZ taper compared to the BZ taper plus a health education control condition. All interventions will be delivered via telehealth to patients recruited from a primary care clinic, where BZ and opioid co-prescribing is common and primary care providers may lack the tools and resources to effectively taper their patients off BZs.
Participants who are co-prescribed benzodiazepines and opioids and report elevated anxiety symptoms will be randomized to one of two conditions: (1) BZ taper with telehealth delivered CBT to facilitate taper; (2) BZ taper with health education control. Participants will be assessed on anxiety symptoms, BZ use/dose, opioids use/dose at baseline, post-treatment, and at a 2-month follow-up.
